
export const EVT_CONTENT = {
  earlyEligible: "Class I evidence for benefit (ASPECTS ≥ 6).",
  largeCore: "SELECT2 and ANGEL-ASPECT trials demonstrate benefit for large core infarcts (ASPECTS 3-5 or Core ≥ 50ml). CAUTION: Higher hemorrhage risk. Recommend interdisciplinary discussion.",
  dawnEligible: "Meets DAWN trial inclusion for thrombectomy 6-24h (Clinical-Core Mismatch).",
  defuseEligible: "Meets DEFUSE-3 trial inclusion (Core < 70ml, Ratio ≥ 1.8).",
  largeCoreLate: "Benefit shown in ANGEL-ASPECT and SELECT2 for large core volumes. Very large cores may be futile. CAUTION: Higher hemorrhage risk. Recommend interdisciplinary discussion.",
  notEligibleLate: "Does not meet DAWN, DEFUSE-3, or SELECT2/ANGEL-ASPECT criteria."
};

export const ELAN_CONTENT = {
  evidence: "Anticoagulation timing determined using ELAN trial protocol. The ELAN trial showed early initiation was non-inferior and appeared safe compared to later initiation.",
  reference: "Reference: Early versus Later Anticoagulation for Stroke with Atrial Fibrillation (ELAN Trial), NEJM 2023."
};

export const SE_CONTENT = {
  evidence: "Source: Glauser T et al. Epilepsy Curr 2016; Kapur J et al. N Engl J Med 2019 (ESETT Trial).",
  stage2Note: "The ESETT Trial found no significant difference in efficacy or safety between Fosphenytoin, Valproate, and Levetiracetam for benzodiazepine-refractory SE."
};

export const MIGRAINE_CONTENT = {
  evidence: "",
  triptan: "Sumatriptan 6 mg Subcutaneous",
  dhe: "Dihydroergotamine (DHE) IV"
};

export const GCA_CONTENT = {
  reference: "Based on 2021 ACR/Vasculitis Foundation guideline and 2023 EULAR imaging recommendations."
};
